S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News

$5.05
+0.22 (+4.55%)
(As of 09/28/2023 ET)
Compare
Today's Range
$4.84
$5.25
50-Day Range
$3.91
$5.90
52-Week Range
$1.56
$9.25
Volume
77,096 shs
Average Volume
130,943 shs
Market Capitalization
$114.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.60

Reviva Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
189.1% Upside
$14.60 Price Target
Short Interest
Bearish
6.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Reviva Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.41) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

696th out of 969 stocks

Pharmaceutical Preparations Industry

328th out of 453 stocks


RVPH stock logo

About Reviva Pharmaceuticals (NASDAQ:RVPH) Stock

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

RVPH Price History

RVPH Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Roth Mkm Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings (RVPH) Receives a New Rating from Roth MKM
RVPH: RECOVER Enrollment Complete
Expert Ratings for Reviva Pharmaceuticals
Where Reviva Pharmaceuticals Stands With Analysts
See More Headlines
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Company Calendar

Last Earnings
8/14/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.60
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+189.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-24,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.60 per share

Miscellaneous

Free Float
15,388,000
Market Cap
$114.38 million
Optionable
Not Optionable
Beta
0.11
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Laxminarayan Bhat Ph.D. (Age 58)
    Founder, CEO, Pres & Director
    Comp: $560k
  • Mr. Narayan Prabhu (Age 51)
    Chief Financial Officer
    Comp: $412.5k













RVPH Stock - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings
or view top-rated stocks.

What is Reviva Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued 1 year price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price forecasts range from $10.00 to $18.00. On average, they anticipate the company's stock price to reach $14.60 in the next year. This suggests a possible upside of 189.1% from the stock's current price.
View analysts price targets for RVPH
or view top-rated stocks among Wall Street analysts.

How have RVPH shares performed in 2023?

Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of 2023. Since then, RVPH stock has increased by 18.8% and is now trading at $5.05.
View the best growth stocks for 2023 here
.

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our RVPH earnings forecast
.

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.26.

What is Reviva Pharmaceuticals' stock symbol?

Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reviva Pharmaceuticals' stock price today?

One share of RVPH stock can currently be purchased for approximately $5.05.

How much money does Reviva Pharmaceuticals make?

Reviva Pharmaceuticals (NASDAQ:RVPH) has a market capitalization of $114.38 million. The company earns $-24,340,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How can I contact Reviva Pharmaceuticals?

Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The official website for the company is www.revivapharma.com. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com.

This page (NASDAQ:RVPH) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -